• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Akorn launches generic antibiotic formulations

Article

Buffalo Grove, IL—Now that patents have expired on two popular antibiotics, Akorn Inc. has launched generic versions of Alcon's Ciloxan and Ocuflox.

Buffalo Grove, IL-Now that patents have expired on two popular antibiotics, Akorn Inc. has launched generic versions of Alcon's Ciloxan and Ocuflox.

Ciprofloxacin ophthalmic solutions USP, 0.3%, and ofloxacin ophthalmic solution USP, 0.3%, were launched in the U.S. market in May. The company anticipates the combined market potential for both products to be more than $40 million.

The new products will be marketed through the company's existing distribution channels.

Related Videos
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
Lorraine Provencher, MD, presenting slides
Katherine Talcott, MD, presenting slides
Katherine Talcott, MD, presenting slides
© 2024 MJH Life Sciences

All rights reserved.